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ABSTRACT 
Background: The weak pharmacovigilance (PV) systems in many developing countries of the world have undoubtedly hampered 
the global quest for safe drug use. Operators of pharmacies and patent medicine stores have important roles to play in developing the 
PV systems in these countries being the main source of medicines for acute conditions. This study aimed to assess the knowledge, 
attitude and practice of pharmacovigilance among operators of pharmacies and patent medicine stores in Sokoto metropolis, Nigeria. 
Materials and Methods: A cross-sectional study was conducted among 249 operators of pharmacies and patent medicine stores 
selected by a multistage sampling technique. Data were collected with a set of pretested self-administered, semi-structured 
questionnaire. 
Results: Although, the majority, 173 (69.5%) of the 249 respondents were aware of PV, less than a fifth (17.3%) had good 
knowledge of it. Despite positive attitude towards PV, only about half, 56 (52.3%) of the 107 respondents that had observed adverse 
drug reactions (ADRs) in clients reported; and of these, only about a tenth (12.8%) formally reported to the organization in charge of 
PV. The most commonly cited reasons for non-reporting were that they did not know where and how to report (51.0%), and 
unavailability of reporting forms (23.5%). 
Conclusion: This study showed poor knowledge of PV and sub-optimal ADRs reporting despite positive attitude towards it by 
operators of pharmacies and patent medicine stores in Sokoto metropolis, Nigeria. Sensitization of the populace and training of 
healthcare providers on PV and ADRs reporting are necessary for revitalizing the PV system in Sokoto State, Nigeria. 
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INTRODUCTION 
Although, pharmacovigilance (PV) is undoubtedly an 
effective strategy for enhancing patients’ safety, as it 
concerns the science and activities relating to the 
detection, assessment, understanding and prevention of 
adverse effects or any other drug-related problem,
1
 the 
weak PV systems in many developing countries of the 
world continue to hamper the global quest for safe drug 
use.  
Timely and comprehensive adverse drug reaction (ADR) 
reporting undoubtedly constitutes the main pillar of a 
strong PV system. A cause for concern is the fact that 
while the prevalence of ADR (defined as a response to a 
drug which is noxious and unintended, and which occurs 
at doses normally used in man for the prophylaxis, 
diagnosis, or therapy of disease, or for the modification 
of physiological function) continues to rise globally and 
has become one of the leading cause of morbidity and 
mortality, it is poorly under-reported worldwide, 
particularly in the developing countries.
2-4
 
The low ADRs reporting rates in many developing 
countries have been attributed to the poor awareness / 
knowledge of PV and ADRs reporting among the 
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healthcare professionals in these countries.  In a study 
among healthcare professionals in Saudi Arabia,
5
 most 
of the respondents (62.5%) were unaware of PV, less 
than half of respondents knew the correct definition of 
PV (44.3%) and ADRs (46.1%), and most of them 
(88.8%) had never reported, submitted or identified any 
ADR reports despite the fact that most of them showed 
positive attitude to PV and ADR reporting. Another 
study among pharmacists in Jordan
6
 reported that only 
25.5% of the respondents knew the correct definition of 
PV, most of them were unaware of the existence of any 
PV centre in the country (84.5%), and of an official 
standardized form for reporting ADRs (71.5%). In 
addition, while 91.2% of respondents had noticed at 
least one ADR in a patient per year, only 19.5% had ever 
reported an ADR. 
The state of the PV systems in the sub-Saharan African 
countries (including Nigeria) is very precarious; a 
comprehensive assessment of the PV systems and their 
performance in 46 countries across the continent showed 
that 87% of the countries do not have a functional PV 
system, 59% do not have a national policy related to 
medicine safety, 70% lack legislation to monitor adverse 
events, and 26% do not have a national PV centre. In 
addition, although 74% have spontaneous adverse event 
reporting systems, less than 50% monitor product 
quality, medication errors or treatment failures through 
the existing systems; and reporting rates were low with 
only 2 countries collecting more than 100 reports per 
million population in 2010.
7
  
This is corroborated by the generally poor knowledge of 
PV and low ADRs reporting obtained in studies 
conducted across the continent. In a study among 
healthcare workers at the Mulago National Referral and 
Teaching Hospital in Uganda,
8
 only 37.7, 18.4 and 
16.6% of respondents knew the tools used in ADR 
reporting, where to report ADR, and had ever reported 
an ADR respectively. Another study among community 
and hospital pharmacists in a selected district of North 
West province, South Africa,
9
 reported that less than 
half of respondents (46.1%) knew the correct definition 
of PV, and despite the fact that most respondents 
(79.4%) regarded PV as a valuable tool, only 44.1% had 
ever reported an ADR. The enormity of the situation in 
sub-Saharan Africa becomes glaringly obvious and 
alarming with the deplorable state of the healthcare 
services across the continent, and with operators of 
patent medicine stores being the main care providers for 
common but potentially deadly illnesses in the 
respective populations across the continent; in addition 
to the prevalent inappropriate drug dispensing practices 
by them, and the fact that their practices are largely 
unregulated.
10
  
Similar to the situation across the continent, operators of 
patent medicine stores are the main source of medicine 
for acute conditions in Nigeria,
11
 and they often engage 
in inappropriate drug dispensing practices as their 
practices are largely unsupervised and unregulated in the 
country.
11,12
 Despite the large population of clientele that 
patronize the patent medicine stores and the risks posed 
by the inappropriate drug dispensing practices of the 
operators, previous studies in Nigeria were focused on 
healthcare professionals (including doctors, nurses and 
pharmacists), and there is limited information on the 
knowledge and practice of PV and ADRs reporting 
among the operators of patent medicine stores in the 
country.  
Strikingly, the previous studies in Nigeria generally 
reported poor knowledge and practice of PV and ADRs 
reporting. A study among 350 resident doctors in 4 
teaching hospitals in Edo and Lagos States of Nigeria
13
 
reported that most of them (78.1%) had inadequate 
knowledge of PV (78.1%), and were unaware of the 
yellow form for reporting ADRs (71.2%). And while 
most of them (92.4%) had observed ADRs in the course 
of their training and practice, only 25.5% of cases were 
reported. Similarly, a study among community 
pharmacists by Oreagba et al,
14
 found that only 55% of 
respondents were aware of PV, and of these, only 18% 
knew its correct definition. In addition, whereas 40% of 
respondents had obtained reports of ADRs from their 
clients at least once a month, only 20% of these had 
reported to relevant authorities, and only 3% actually 
reported to the National Pharmacovigilance Centre. A 
study among patent medicine vendors (PMVs) in Ekiti 
State, Nigeria,
15
 reported very low ADRs reporting 
(3.8%) and this was majorly attributed to lack of training 
on ADRs reporting (92.5%) and fear of indictment 
(61.3%). While these findings elucidate the importance 
of assessment of knowledge and practice of PV among 
healthcare providers by identifying the factors 
responsible for the weak PV system in the country, it 
emphasizes the need to conduct such studies in other 
parts of the country where such studies have not been 
carried out to know the local pattern and peculiarities. 
This would contribute significantly in generating vital 
information for designing appropriate strategies for 
developing strong PV systems and optimal ADRs 
reporting in such places. The knowledge, attitude and 
practice of PV among operators of pharmacies and 
patent medicine stores in Sokoto, Nigeria, have not been 
examined, thus making it necessary to conduct this 
study. 
MATERIALS AND METHODS 
Study Design and Population 
A cross-sectional study was conducted among operators 
of pharmacies and patent medicine stores in Sokoto 
metropolis, North-Western Nigeria, from September to 
November 2017. Operators of pharmacies and patent 
medicine stores that were aged 18 years and above, and 
have worked for at least 6 months in the respective 
pharmacies and patent medicine stores were considered 
eligible for this study. The sample size was estimated at 
246 using the Fisher’s formula for calculating sample 
size for cross-sectional studies,
16
 a 20.0% prevalence of 
adverse drug reactions reporting among community 
pharmacists in a previous study,
14
 and a precision level 
of 5%. This was adjusted upwards to 259 based on an 
anticipated participant response rate of 95%.  
The eligible participants were selected by a multistage 
sampling technique. At the first stage, Sokoto metropolis 
was divided into 12 business districts and 8 of them 
were selected by simple random sampling using the 
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balloting option. At the second stage, the selection of 
pharmacies and patent medicine stores in each of the 
selected districts was done by a systematic sampling 
technique using the list of pharmacies and patent 
medicine stores in the respective districts to constitute 
the sampling frame (one of 2, and 1 of 3 pharmacies and 
patent medicine stores were selected respectively). At 
the third stage, the selection of participants in the 
selected pharmacies and patent medicine stores was 
done by a systematic sampling technique using the staff 
list in the respective pharmacies and patent medicine 
stores to constitute the sampling frame. One of every 3 
eligible participants was selected in the selected 
pharmacies and patent medicine stores at the end of 
which 260 participants were selected. 
Data Collection and Analysis 
A standardized, structured, self-administered 
questionnaire was developed and used to obtain 
information on the participants’ socio-demographic 
characteristics, and their knowledge, attitude and 
practice of pharmacovigilance. It was reviewed by 
researchers in the Department of Community Health, 
Usmanu Danfodiyo University, Sokoto, Nigeria. 
Corrections were made based on their inputs on content 
validity. The questionnaire was pretested on 20 
operators of pharmacies and patent medicine stores in 
one of the business districts that were not selected for 
the study; some questions were rephrased for clarity 
based on the observations made during the pretesting. 
Five resident doctors assisted in questionnaire 
administration after being trained on the conduct of 
survey research, the objectives of the study, and 
questionnaire administration.  
Data were analyzed using IBM Statistical Package for 
the Social Sciences (SPSS) Version 24.0 statistical 
computer software package. Respondents’ knowledge of 
pharmacovigilance was scored and graded on a 10-point 
scale. One point was awarded for a correct response, 
while a wrong response or a non-response received no 
points. This gives a minimum score of ‘0’ and a 
maximum score of ‘10’ points. Those that scored ≥ 6 of 
10 points were considered as having ‘good’ knowledge, 
while those that scored < 6 of 10 points were graded as 
having ‘poor’ knowledge. Frequency distribution tables 
were constructed; and cross tabulations were done to 
examine the relationship between categorical variables. 
The Chi‑ square test was used for bivariate analysis 
involving categorical variables. All levels of significance 
were set at p < 0.05. 
Ethical Consideration 
Institutional ethical clearance was obtained from the 
Ethical Committee of Sokoto State Ministry of Health, 
Sokoto, Nigeria. Permission to conduct the study in the 
pharmacies and patent medicine stores was obtained 
from the PMVs’ union leaders and the owners of the 
selected pharmacies and patent medicine stores. The 
study objectives were explained to the participants and 
informed written consent was obtained from them before 
the data collection. 
 
RESULTS 
Socio-demographic characteristics of respondents 
Two hundred and forty-nine out of the 260 
questionnaires administered were completely filled and 
retrieved, giving a response rate of 95.8%. The ages of 
the respondents ranged from 18 to 52 years, but majority 
of them 133 (53.4%) were aged 20 – 29 years. The 
majority of respondents were males (189, 75.9%), single 
(163, 65.5%), and practiced Islam as religion (140, 
56.2%). Most of the respondents had diploma or 
bachelorette degree (80.3%), and have practiced for less 
than 10 years (86.7%). The majority of respondents were 
employees (77.1%), and they practiced in patent 
medicine stores (56.2%) as shown in Table 1. 
Table 1: Socio-demographic characteristics of 
respondents 
 
Awareness of pharmacovigilance by respondents 
The majority, 173 (69.5%) of the 249 respondents had 
heard of pharmacovigilance (PV), with the most 
common source of information being lectures / seminars 
/ workshops (60.7%). About a tenth of respondents 
(13.3%) also obtained information on PV from their 
colleagues (Table 2).  
Variables Frequency (%) 
 n = 249 
Age group (years) 
<20 
20-29 
30-39 
≥40 
 
 
33 (13.3) 
133 (53.4) 
62 (24.9) 
21 (8.4) 
Sex 
Male 
Female 
 
 
189 (75.9) 
60 (24.1) 
 
Marital status 
Single 
Married 
Separated 
 
 
163 (65.5) 
85 (34.1) 
1 (0.4) 
 
Religion 
Islam 
Christianity 
 
 
140 (56.2) 
109 (43.8) 
Level of education 
Primary and below 
Secondary 
Post-secondary (diploma)  
University (bachelorette) 
 
 
7 (2.8) 
42 (16.9) 
124 (49.8) 
76 (30.5) 
Length of practice (years) 
1-9 
≥10 
 
 
215 (86.3) 
34 (13.7) 
Place of practice 
Pharmacy 
Patent medicine store 
 
 
109 (43.8) 
140 (56.2) 
Status 
Owner 
Employee 
 
57 (22.9) 
192 (77.1) 
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Table 2: Awareness of pharmacovigilance by 
respondents 
Respondents’ knowledge of pharmacovigilance 
Only 43 (17.3%) of the 249 respondents had good 
knowledge of pharmacovigilance (PV). About a third 
knew the correct definition of PV (36.1%) and its main 
purpose (31.3%).  Also, about a third knew the correct 
definition of an adverse drug reaction (35.7%), and that 
all healthcare providers should report an ADR (36.1%). 
Although, the majority of respondents (64.3%) knew the 
organization in charge of adverse drug reactions (ADRs) 
reporting, less than half of them knew the benefits of 
ADRs reporting (38.2%), and that all ADRs should be 
reported (41.4%) as shown in Table 3. There was no 
association between good knowledge of 
pharmacovigilance and any of the respondents’ socio-
demographic variables. 
 
Table 3: Respondents’ knowledge of pharmacovigilance 
 
 
 
 
 
 
 
 
 
 
 
 
 
NAFDAC: National Agency for Food and Drug Administration and Control 
ADR: Adverse drug reaction 
Respondents’ attitude towards pharmacovigilance 
Most of the 249 respondents showed positive attitude 
towards pharmacovigilance, as they believed that 
adverse drug reactions (ADRs) reporting is a 
professional obligation (232, 93.2%), and necessary 
(247, 97.6%). Also, most of them believed that ADRs 
reporting will increase clients’ safety (240, 96.4%) and 
should be made mandatory (222, 89.2%). Most of them 
also believed that pharmacovigilance should be taught in 
detail to healthcare providers (241, 96.8%) and were 
willing to participate in ADRs reporting (235, 95.6%) as 
shown in Figure 1. 
 
 
Figure 1: Respondents’ attitude towards pharmacovigilance 
Variables 
 
Frequency 
(%) 
Ever heard of pharmacovigilance 
(n = 249) 
Yes 
No 
 
 
 
173 (69.5) 
76 (39.5) 
Main source of information  
(n = 173) 
Lectures / seminars / workshops 
Journals / books 
Radio / television 
Newspaper / magazines 
Colleagues 
 
 
105 (60.7) 
16 (9.2) 
16 (9.2) 
13 (7.5) 
23 (13.3) 
Variables 
 
Frequency (%) 
(n = 249) 
Knowledge of pharmacovigilance 
Knew the correct definition of pharmacovigilance 
Knew the main purpose of pharmacovigilance 
Knew the correct definition of an adverse drug reaction 
Knew that all adverse drug reactions should be reported 
Knew that NAFDAC is the organization in charge of ADR reporting in Nigeria 
Knew that all healthcare providers should report an ADR 
Knew that the yellow form is used in reporting adverse drug reactions 
Knew the information that should be entered into the ADR reporting form 
Knew where ADR reporting form can be obtained from, and where it should be submitted 
after completing it. 
Knew the benefits of ADR reporting 
 
 
90 (36.1) 
78 (31.3) 
89 (35.7) 
103 (41.4) 
160 (64.3) 
90 (36.1) 
42 (16.9) 
113 (45.4) 
39 (15.7) 
 
95 (38.2) 
Knowledge grade 
Good 
Poor 
 
43 (17.3) 
206 (82.7) 
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Respondents’ pharmacovigilance practices 
Only about a quarter of respondents had attended a 
seminar on adverse drug reaction (ADR) reporting 
(28.5%), and had seen an ADR reporting form (26.1%). 
Close to half, 107 (43.0%) of the 249 respondents had 
observed an ADR in clients; of these, only about half 
(52.3%) reported the ADR observed, mostly to the shop 
owners (44.6%), their colleagues (16.1%) and 
supervisors (14.3%); only about a tenth (12.8%) of them 
reported formally to either the State NAFDAC office or 
Zonal Pharmacovigilance Centre. The most common 
reasons for not reporting the ADRs observed in clients 
were that they did not know where and how to report 
(51.0%), and unavailability of reporting forms in their 
pharmacies / stores (23.5%) as shown in Table 4. 
  
Table 4: Respondents’ pharmacovigilance practices 
 
*Multiple responses allowed;  
 ADR: adverse drug reaction; 
 NAFDAC: National Agency for Food and Drug Administration and Control 
 
DISCUSSION 
This study assessed the knowledge, attitude and practice 
of pharmacovigilance among operators of pharmacies 
and patent medicine stores in Sokoto metropolis, 
Nigeria. The high educational attainment of the 
respondents in this study with most of them (80.3%) 
having diploma or bachelorette degree is not surprising 
considering the fact their job entails being able to 
identify the drugs requested by clients, read the 
instructions on the drug label and counsel their clients on 
the dosage regimen, the likely side effects, and what to 
do should they experience any adverse drug reaction. 
This finding is in agreement with the finding in studies 
conducted among operators of pharmacies and patent 
medicine stores in other cities in Nigeria, as they 
majorly reported high educational attainment among the 
respondents.
17-19
    
Whereas, awareness of pharmacovigilance is higher 
among the respondents in this study (69.5%) as 
compared to the finding in a study among community 
Variables 
 
Frequency (%) 
Ever attended a seminar on ADR reporting (n = 249) 
Yes 
No 
 
79 (28.5) 
178 (71.5) 
Ever seen an ADR reporting form (n = 249) 
Yes 
No 
 
65 (26.1) 
184 (73.9) 
 
Ever observed an ADR in clients (n = 249) 
Yes 
No 
 
107 (43.0) 
142 (57.0) 
Types of ADR seen (n = 107)* 
Vomiting 
Skin rashes 
Itching 
Eye symptoms 
Body swelling 
Others 
 
 
50 (45.9) 
66 (60.6) 
33 (30.3) 
18 (16.5) 
16 (14.7) 
97 (89.0) 
Ever reported an ADR observed in clients (n = 107) 
Yes 
No 
 
56 (52.3) 
51 (47.7) 
Where / who observed ADR was reported (n = 56) 
Colleagues 
Supervisor 
Owner of shop 
Drug distributor 
State NAFDAC office 
Zonal Pharmacovigilance Centre 
 
 
9 (16.1) 
8 (14.3) 
25 (44.6) 
7 (12.5) 
3 (5.7) 
4 (7.1) 
Main reason for not reporting observed ADR (n = 51) 
Did not know where and how to report 
Did not consider it important 
To maintain clients’ confidentiality 
Reporting forms not available in the pharmacy / store 
Fear of legal liability 
 
26 (51.0) 
9 (17.6) 
2 (3.9) 
12 (23.5) 
2 (3.9) 
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pharmacists in Lagos, South West Nigeria
14
 that 
reported that only about half (55.0%) of respondents 
were aware of PV, it is much lower than the very high 
awareness (100%) reported in another study conducted 
among pharmacists in two states in South-eastern 
Nigeria.
20
 The wide variation in the awareness of PV 
among operators of pharmacies and patent medicine 
stores across the country underscores the need for the 
National Agency for Food and Drug Administration and 
Control to organize regular sensitization campaigns on 
PV across the country.  
The poor knowledge of PV among the respondents in 
this study with less than a fifth of them (17.3%) having 
good knowledge of PV, and only about a third knowing 
the correct definition of PV and its main purpose is 
surprising in view of their high educational attainment. It 
is also surprising that only about a third of the 
respondents in this study knew the correct definition of 
an adverse drug reaction (35.7%), and that the yellow 
form is used in reporting adverse drug reactions 
(36.1%). However, the main cause for concern is the 
generally poor knowledge of pharmacovigilance and 
adverse drug reactions reporting in studies conducted 
among community pharmacists and patent medicine 
vendors in Nigeria
14,15,20
 and other developing countries 
including South Africa,
9
 Jordan,
6
 Yemen,
21
 India,
4
 and 
Saudi Arabia,
22
 as they imply poor sensitization of 
healthcare providers on PV as a result of the weak PV 
systems in these countries.  
While the finding of close to half of the respondents in 
this study (43.0%) ever observing an adverse drug 
reaction in clients suggests a high burden of the problem 
in Sokoto, Nigeria, the finding of about half (52.3%) of 
those that had observed an ADR in clients reporting it, 
with only a tenth (12.8%) of these reporting formally to 
either the State NAFDAC office or Zonal 
Pharmacovigilance Centre is worrisome as it indicates a 
very weak PV system in Sokoto State, Nigeria (as most 
of the pharmacies and patent medicine stores in the state 
are located in Sokoto metropolis). This is obvious in 
view of the positive attitude towards PV by most of the 
respondents (particularly their willingness to participate 
in ADRs reporting), and the fact that only about a 
quarter of respondents (28.5%) had attended a seminar 
on ADR reporting, and the main reasons cited for not 
reporting the ADRs they had observed in their clients 
were that they did not know where and how to report 
(51.0%), and unavailability of ADRs reporting forms in 
their pharmacies / stores. It is therefore imperative for 
the Sokoto State NAFDAC office, in collaboration with 
the National and Zonal Pharmacovigilance Centers to 
sensitize the populace and train healthcare providers 
(particularly, operators of pharmacies and patient 
medicine stores) on PV and ADRs reporting in order to 
revitalize the PV system in the state.  
CONCLUSION 
This study showed poor knowledge of 
pharmacovigilance (PV) and sub-optimal adverse drug 
reactions (ADRs) reporting (despite positive attitude 
towards it) by operators of pharmacies and patent 
medicine stores in Sokoto metropolis, Nigeria. 
Sensitization of the populace and training of healthcare 
providers on PV and ADRs reporting are necessary for 
revitalizing the PV system in Sokoto State, Nigeria. 
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